PDL BioPharma (NASDAQ:PDLI) will announce its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $0.11 per share for the quarter.
Shares of PDL BioPharma (PDLI) opened at $2.47 on Monday. The company has a current ratio of 3.16, a quick ratio of 3.10 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $381.22, a PE ratio of 4.94 and a beta of 0.48. PDL BioPharma has a twelve month low of $1.96 and a twelve month high of $3.55.
Several brokerages have recently issued reports on PDLI. Zacks Investment Research cut PDL BioPharma from a “buy” rating to a “hold” rating in a report on Monday, January 8th. BidaskClub cut PDL BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Cowen reaffirmed a “hold” rating and issued a $3.00 target price on shares of PDL BioPharma in a report on Friday, October 27th. Finally, ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a report on Saturday, November 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $3.33.
ILLEGAL ACTIVITY WARNING: “PDL BioPharma (PDLI) to Release Earnings on Wednesday” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/19/pdl-biopharma-pdli-to-release-earnings-on-wednesday.html.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.